Wallace H. Coulter Department of Biomedical Engineering , Georgia Institute of Technology and Emory University , Atlanta , Georgia 30322 , United States.
ACS Nano. 2019 Sep 24;13(9):9702-9706. doi: 10.1021/acsnano.9b05716. Epub 2019 Aug 30.
Effective therapies for cardiac repair and regeneration after myocardial infarction (MI) are rather limited. Although microRNAs (miRs) are known to play an important role in improving cardiac function after MI at a cellular level, delivering and retaining miRs at the target site has been challenging. To address this dilemma, several miR carriers have been developed, but these face their own limitations such as immunogenicity and poor targeting to the infarct site. In this Perspective, we summarize different mechanisms for miR administration and localization to cardiac tissue, with a specific focus on the clinically relevant injectable hydrogel and nanoparticle system developed by Yang and reported in this issue of We also highlight future directions for this field and outline the remaining unanswered questions.
有效的心肌梗死后心脏修复和再生治疗方法相当有限。尽管 microRNAs（miRs）在改善心肌梗死后的心脏功能方面在细胞水平上起着重要作用，但将 miR 递送到靶位并保留在靶位一直具有挑战性。为了解决这一难题，已经开发了几种 miR 载体，但这些载体都面临着自身的局限性，如免疫原性和对梗死部位的靶向性差。在本观点中，我们总结了 miR 给药和定位到心脏组织的不同机制，特别关注 Yang 等人在本期杂志上报道的临床相关可注射水凝胶和纳米颗粒系统。我们还强调了该领域的未来发展方向，并概述了仍未解决的问题。
